Initial results of neoadjuvant TCH regimen in patients with HER2-positive stage II-III breast cancer at 108 Military Central hospital
Main Article Content
Abstract
A descriptive study was conducted to evaluate the initial outcomes of neoadjuvant chemotherapy using TCH regimen in 35 patients with HER2-positive stage II-III breast cancer treated at 108 Military Central Hospital from December 2024 to December 2025. The patients mean age was 51.7 years old (32 – 74 years old). Clinical stages II and III accounted for 60% and 40%, respectively. Hormone receptor positive was observed in 51.4% of cases. The overall clinical response rate reached 97.2%. The total pathologic complete response (tpCR) rate was 45.7%; no significant correlation was identified between tpCR and analyzed predictive factors. The most common grade 3-4 adverse event was neutropenia. There were no treatment-related death or permanent discontinuation due to toxicity. Initial results indicate that neoadjuvant TCH therapy for HER2-positive stage II-III breast cancer yields a high response rate with a manageable safety profile.
Article Details
Keywords
HER2-positive breast cancer, neoadjuvant chemotherapy, TCH regimen
References
2. Zhang X. Molecular classification of breast cancer: relevance and challenges. Arch Pathol Lab Med. 2023; 147(1): 46-51. doi:10.5858/arpa.2021-0495-RA.
3. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8): 1160-1167. doi:10.1200/JCO.2008.18.1370.
4. Tarver T. Breast Cancer Facts & Figures 2021. American Cancer Society; 2021.
5. Tiwari SR, Mishra P, Raska P. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. Breast Cancer Res Treat. 2016; 158(1): 189-193. doi:10.1007/s10549-016-3862-2.
6. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228-247. doi:10.1016/j.ejca.2008.10.026.
7. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer: pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993; 16(3): 223-228. doi:10.1097/00000421-199306000-00006.
8. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. US Department of Health and Human Services; 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5.0.pdf.
9. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13(1): 25-32. doi:10.1016/S1470-2045(11)70336-9.
10. Gao H-F, Wu Z, Lin Y. Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial. Therapeutic Advances in Medical Oncology. 2021; 13: 17588359211009004.
11. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010; 375(9712): 377-384. doi:10.1016/S0140-6736(09)61964-4.
12. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010; 28(12): 2024-2031. doi:10.1200/JCO.2009.23.8451.
13. Phùng TH. Kết quả điều trị bổ trợ trước phác đồ hóa chất kết hợp trastuzumab và pertuzumab trên ung thư vú có HER2-NEU dương tính. Tạp chí Y học Việt Nam. 2022; 509(1): 142-146. doi:10.51298/vmj.v509i1.1890.